Sawyer & Company Inc Makes New Investment in Stryker Corporation $SYK

Sawyer & Company Inc acquired a new position in shares of Stryker Corporation (NYSE:SYK) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,878 shares of the medical technology company’s stock, valued at approximately $1,343,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Mitchell Mcleod Pugh & Williams Inc. raised its holdings in Stryker by 1.2% in the 1st quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 2,678 shares of the medical technology company’s stock worth $880,000 after acquiring an additional 31 shares during the period. Community Bank & Trust Waco Texas grew its position in shares of Stryker by 2.3% in the second quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company’s stock valued at $439,000 after purchasing an additional 31 shares during the last quarter. Cornerstone Financial Management LLC grew its position in shares of Stryker by 66.0% in the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. NWF Advisory Services Inc. grew its position in shares of Stryker by 2.3% in the second quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company’s stock valued at $463,000 after purchasing an additional 33 shares during the last quarter. Finally, Harold Davidson & Associates Inc. increased its stake in shares of Stryker by 0.4% in the first quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company’s stock worth $2,848,000 after purchasing an additional 34 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Debra King sold 826 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronda Stryker sold 50,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the sale, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. The trade was a 2.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is currently owned by company insiders.

Stryker Stock Performance

Shares of SYK traded down $7.07 during trading hours on Wednesday, reaching $297.33. 1,193,869 shares of the company traded hands, compared to its average volume of 2,450,214. The stock’s fifty day moving average is $297.53 and its 200 day moving average is $312.37. The stock has a market cap of $114.05 billion, a P/E ratio of 30.77, a price-to-earnings-growth ratio of 1.92 and a beta of 0.78. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a 1-year low of $267.00 and a 1-year high of $392.55.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter last year, the company earned $3.13 earnings per share. The firm’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts anticipate that Stryker Corporation will post 14.93 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Analyst Ratings Changes

SYK has been the subject of several research analyst reports. Citigroup cut their price objective on Stryker from $399.00 to $360.00 and set a “buy” rating for the company in a research report on Thursday, September 10th. JPMorgan Chase & Co. lowered their target price on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Canaccord Genuity Group dropped their price target on Stryker from $400.00 to $385.00 and set a “buy” rating on the stock in a research report on Friday, September 18th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Stryker in a research report on Wednesday, October 7th. Finally, Argus set a $370.00 price target on Stryker in a report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $369.00.

Stryker Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.